58 Real-life single-centre experience of Tocilizumab-associated neutropenia in children with juvenile idiopathic arthritis (JIA)
BackgroundTocilizumab, approved for treatment of children with Systemic-onset-JIA (SoJIA) and polyarticular-JIA (pJIA) is efficacious and well-tolerated. Transient neutropenia is a side-effect of treatment.AimChart-review of children treated with Tocilizumab to report on Tocilizumab-associated-neuto...
Saved in:
Published in: | Archives of disease in childhood 2019-11, Vol.104 (Suppl 4), p.A23 |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | BackgroundTocilizumab, approved for treatment of children with Systemic-onset-JIA (SoJIA) and polyarticular-JIA (pJIA) is efficacious and well-tolerated. Transient neutropenia is a side-effect of treatment.AimChart-review of children treated with Tocilizumab to report on Tocilizumab-associated-neutopenic-episodes.MethodsRetrospective review of patients receiving Tocilizumab (January 2010-January 2019). Patients with extended-oligoarticular-JIA (ExO-JIA), pJIA and SoJIA reviewed in more detail to ascertain frequency of neutropenia and related-factors. For analysis, ExO-JIA and pJIA were combined to create an ExO/pJIA group. Neutropenia defined as neutrophils |
---|---|
ISSN: | 0003-9888 1468-2044 |
DOI: | 10.1136/archdischild-2019-gosh.58 |